Chartwell Investment Partners LLC Takes Position in Neurocrine Biosciences, Inc. (NBIX)

Chartwell Investment Partners LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, Holdings Channel reports. The institutional investor acquired 121,955 shares of the company’s stock, valued at approximately $6,176,000. Chartwell Investment Partners LLC owned about 0.14% of Neurocrine Biosciences as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Dynamic Capital Management Ltd increased its stake in Neurocrine Biosciences by 125.1% in the third quarter. Dynamic Capital Management Ltd now owns 43,845 shares of the company’s stock valued at $2,220,000 after buying an additional 24,363 shares during the last quarter. Creative Planning increased its stake in Neurocrine Biosciences by 0.7% in the third quarter. Creative Planning now owns 5,338 shares of the company’s stock valued at $270,000 after buying an additional 38 shares during the last quarter. First Mercantile Trust Co. increased its stake in Neurocrine Biosciences by 94.9% in the third quarter. First Mercantile Trust Co. now owns 3,897 shares of the company’s stock valued at $197,000 after buying an additional 1,897 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Neurocrine Biosciences by 13.6% in the third quarter. BNP Paribas Arbitrage SA now owns 14,472 shares of the company’s stock valued at $733,000 after buying an additional 1,736 shares during the last quarter. Finally, Royal Bank of Canada increased its stake in Neurocrine Biosciences by 3.1% in the second quarter. Royal Bank of Canada now owns 477,152 shares of the company’s stock valued at $21,686,000 after buying an additional 14,449 shares during the last quarter. Institutional investors and hedge funds own 97.73% of the company’s stock.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded down 2.03% during trading on Friday, reaching $44.44. 1,238,520 shares of the company were exchanged. The stock has a 50 day moving average price of $41.38 and a 200 day moving average price of $46.40. Neurocrine Biosciences, Inc. has a 12 month low of $32.18 and a 12 month high of $55.15. The firm’s market capitalization is $3.86 billion.

TRADEMARK VIOLATION WARNING: “Chartwell Investment Partners LLC Takes Position in Neurocrine Biosciences, Inc. (NBIX)” was first reported by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at http://sleekmoney.com/chartwell-investment-partners-llc-takes-position-in-neurocrine-biosciences-inc-nbix/1657039.html.

Several equities research analysts have recently commented on the stock. Oppenheimer Holdings, Inc. assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday, November 22nd. They set a “market perform” rating and a $55.00 price objective for the company. Citigroup Inc. began coverage on shares of Neurocrine Biosciences in a research report on Tuesday, November 22nd. They set a “market perform” rating and a $55.00 target price for the company. They noted that the move was a valuation call. Piper Jaffray Companies restated an “overweight” rating and set a $96.00 target price on shares of Neurocrine Biosciences in a research report on Friday. ICAP restated an “outperform” rating and set a $55.00 target price on shares of Neurocrine Biosciences in a research report on Friday. Finally, BMO Capital Markets restated an “outperform” rating and set a $72.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a research report on Thursday, October 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have issued a buy rating to the company. Neurocrine Biosciences has a consensus rating of “Buy” and a consensus price target of $65.31.

In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 1,625 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $40.63, for a total transaction of $66,023.75. Following the transaction, the insider now directly owns 114,704 shares of the company’s stock, valued at $4,660,423.52. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Christopher Flint Obrien sold 25,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $52.84, for a total transaction of $1,321,000.00. Following the transaction, the insider now directly owns 30,044 shares in the company, valued at $1,587,524.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 57,816 shares of company stock worth $2,708,036. 4.80% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/chartwell-investment-partners-llc-takes-position-in-neurocrine-biosciences-inc-nbix/1657039.html

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *